Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3093 |
|
Actual shortage: | 246 (8%) | |
Anticipated shortage: | 15 (0%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2823 (91%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
31 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-HYDROXYUREA | 500MG | CAPSULE | Resolved | 2017-08-14 | 2017-12-07 | 19129 |
APO-HYDROXYUREA | 500MG | CAPSULE | Resolved | 2019-08-08 | 2020-06-24 | 91143 |
APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2020-08-14 | 2020-11-18 | 122276 |
APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2022-12-09 | 2023-01-31 | 177609 |
APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2023-02-02 | 2023-02-09 | 183489 |
APO-HYDROXYUREA | 500MG | CAPSULE CAPSULE | Resolved | 2023-08-18 | 2023-09-12 | 202406 |
APO-IBUPROFEN | 400MG | TABLET | Resolved | 2021-03-19 | 2021-06-07 | 136019 |
APO-IBUPROFEN | 400MG | TABLET | Resolved | 2021-04-09 | 2021-05-01 | 137250 |
APO-IBUPROFEN | 200MG | TABLET | Resolved | 2022-02-11 | 2022-05-14 | 154762 |
APO-IBUPROFEN | 400MG | TABLET | Resolved | 2023-01-06 | 2023-02-09 | 180109 |
APO-IBUPROFEN | 200MG | TABLET | Resolved | 2024-03-01 | 2024-03-29 | 221087 |
APO-IBUPROFEN | 400MG | TABLET | Resolved | 2024-03-15 | 2024-04-05 | 222470 |
APO-IBUPROFEN | 200MG | TABLET | Resolved | 2019-02-24 | 2020-04-01 | 76717 |
APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2023-04-14 | 2023-04-21 | 189638 |
APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2023-11-17 | 2023-12-01 | 210733 |
APO-IBUPROFEN TAB 600MG | 600MG | TABLET | Resolved | 2024-01-12 | 2024-03-29 | 215967 |
APO-IMATINIB | 400MG | TABLET | Resolved | 2017-07-31 | 2017-09-06 | 17609 |
APO-IMATINIB | 400MG | TABLET | Resolved | 2017-11-28 | 2018-04-18 | 31010 |
APO-IMATINIB | 400MG | TABLET | Resolved | 2018-07-31 | 2018-11-15 | 56986 |
APO-IMATINIB | 400MG | TABLET | Resolved | 2018-11-30 | 2019-01-10 | 68221 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |